Buys Michael J, Bayless Kimberlee, Romesser Jennifer, Anderson Zachary, Patel Shardool, Zhang Chong, Presson Angela P, Beckstrom Julie, Brooke Benjamin S
is an Anesthesiologist, is a Nurse Practitioner, is a Psychologist, and are Pharmacists, all at the Salt Lake City VA Medical Center in Utah. is a Research Nurse and is an Associate Professor, both in the Department of Surgery; Michael Buys is an Associate Professor in the Department of Anesthesiology; is a Statistician, and is a Research Associate Professor, both in the Department of Internal Medicine and Epidemiology; all at the University of Utah in Salt Lake City.
Fed Pract. 2020 Oct;37(10):472-478. doi: 10.12788/fp.0053.
For patients with existing chronic opioid use or a history of substance use disorder, often little presurgical planning or postsurgical coordination of care among surgeons, primary care providers, or addiction care providers occurs.
In 2018, we developed the Transitional Pain Service (TPS) to identify at-risk patients as soon as they were indicated for surgery, to allow time for evaluation, education, and developing an individualized pain plan, and opioid taper prior to surgery if indicated. An electronic dashboard registry of surgical episodes provided data to TPS providers and included baseline history, morphine equivalent daily dose, and patient-reported pain outcomes, using measures from the Patient-Reported Outcome Measurement System for pain intensity, pain interference, and physical function, and a pain-catastrophizing scale score.
Two-hundred thirteen patients were enrolled between January and December 2018. Nearly all (99%) patients had ≥ 1 successful follow-up within 14 days after discharge; 96% had ≥ 1 follow-up between 14 and 30 days after surgery; and 72% had completed personal follow-up 90 days after discharge.
In 2018 the overall use of opioids after orthopedic surgery decreased by > 40% from the previous year. Despite this more restricted use of opioids, pain interference and physical function scores indicated that surgical patients do not seem to experience increased pain or reduced physical function.
对于已有慢性阿片类药物使用史或物质使用障碍病史的患者,外科医生、初级保健提供者或成瘾护理提供者之间通常很少进行术前规划或术后护理协调。
2018年,我们设立了过渡性疼痛服务(TPS),以便在有手术指征时尽快识别高危患者,留出时间进行评估、教育并制定个性化疼痛计划,如有指征则在术前逐渐减少阿片类药物用量。手术事件的电子仪表盘登记系统向TPS提供者提供数据,包括基线病史、每日吗啡当量剂量以及患者报告的疼痛结果,采用患者报告结果测量系统中关于疼痛强度、疼痛干扰和身体功能的测量指标以及疼痛灾难化量表评分。
2018年1月至12月期间共纳入213例患者。几乎所有(99%)患者在出院后14天内至少有1次成功随访;96%的患者在术后14至30天之间至少有1次随访;72%的患者在出院90天后完成了个人随访。
2018年,骨科手术后阿片类药物的总体使用量较上一年减少了40%以上。尽管阿片类药物的使用更加受限,但疼痛干扰和身体功能评分表明,手术患者似乎并未经历疼痛加剧或身体功能下降。